Note: This resource does not reflect recent changes that have been implemented by the Trump administration, including a foreign aid review and restructuring. For more information, see KFF’s Overview of President Trump’s Executive Actions on Global Health. This resource was originally published on February 4, 2025, and will be updated as needed to reflect additional developments.

Introduction

U.S. engagement in global health is multifaceted and includes a broad range of activities, one of which is financially supporting health efforts worldwide. As the largest donor to global health in the world, the U.S. supports bilateral efforts, directly funding implementation of global health activities in partner countries, and multilateral health institutions (i.e., international organizations that pool support from multiple donors for one or more areas of global health). Here are 10 things to know about U.S. funding for global health:

1. U.S. global health funding totals approximately $12 billion but only represents less than 1% of the federal budget.

U.S. global health funding, most of which is part of the broader U.S. foreign aid budget that includes funding for development, economic, and humanitarian assistance programs, totaled $12.4 billion (through regular appropriations) in FY 2025 but accounted for less than 1% of the federal budget, which totaled approximately $1.6 trillion (see Figure 1). In some years, on top of regular appropriations, global health funding is also provided through emergency supplemental funding to address disease outbreaks, but this funding generally makes up a small piece of the federal budget pie.

Figure 1

2. U.S. funding for global health is complex!

Funding supports multiple program areas at several agencies and departments for both bilateral and multilateral efforts and is provided both annually and in emergency situations.

Program Areas

The U.S. government supports global health efforts aimed at addressing numerous areas, funding programs to address HIV (through PEPFAR, the President’s Emergency Plan for AIDS Relief), tuberculosis (TB), malaria (through PMI, the President’s Malaria Initiative), maternal and child health (MCH), nutrition, family planning and reproductive health (FP/RH), neglected tropical disease (NTDs),  global health security, as well as the vulnerable children program and other public health threats, which include programs for cross-cutting health activities like the Health Reserve Fund and the global health workforce through the Global Health Workforce Initiative (see more detail on program areas below).

Agencies/Departments

The U.S. supports these efforts via several agencies, departments, and accounts. Agencies and departments that receive funding for global health include the U.S. Department of State (State), U.S. Agency for International Development (USAID), Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), and the Department of Defense (DoD). In addition, funding is provided through several accounts at State and USAID including: the Global Health Programs (GHP) account at State and USAID, Contributions to International Organizations (CIO) and International Organizations and Programs (IO&P) accounts at State, and the Assistance for Europe, Eurasia and Central Asia (AEECA), Development Assistance (DA), Economic Support Fund (ESF) and International Disaster Assistance (IDA) accounts at USAID (see more detail on agencies, departments, and accounts below).

Bilateral and Multilateral Funding

Funding is provided bilaterally, directly supporting the implementation of global health activities in almost 80 partner countries that span six regions across the globe (see more detail on bilateral efforts below), and multilaterally, providing support to international organizations that pool funding from multiple donors for one or more areas of global health. Multilateral health institutions the U.S. supports through financial contributions include the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund), Gavi the Vaccine Alliance (Gavi), United Nations Children’s Fund (UNICEF), World Health Organization (WHO), Pan American Health Organization (PAHO), Joint United Nations Programme on HIV/AIDS (UNAIDS), United Nations Population Fund (UNFPA), TB Drug Global Drug Facility, and the Pandemic Fund (see more detail on these multilateral health efforts below).

Regular Annual and Emergency Supplemental Appropriations

Finally, U.S. funding for global health is comprised of funding provided through the regular appropriations process, which takes place annually (see more detail on the federal budget process below), and through emergency supplemental funding for disease outbreaks, which often takes place during public health emergencies.

3. U.S. global health funding is determined annually through a multi-step process that involves the President and Congress.

U.S. funding for global health is discretionary¹  and determined annually through the U.S. federal budget process, which is initiated by the President and is ultimately set by Congress (see Table 1), which specifies most, but not all, funding (about 99% each year) by agency and program area in annual appropriations bills. Funding for some global health activities that are not specified by Congress are determined at the agency level (more details in the following section).

The President’s request often differs from Congress’ enacted levels; in some years, the difference between the request and enacted levels is negligible, while in others, it is significant. For instance, from FY 2018 – FY 2021, the President’s request was significantly lower than what Congress ultimately approved (see Figure 2). Until recently (FY 2023 and FY 2024), Congress provided higher funding levels than the President’s request over the past decade.

Figure 2

4. The majority of U.S. funding for global health is channeled through the Department of State and U.S. Agency for International Development.

The U.S. government funds and carries out its global health efforts through multiple agencies and departments, although most funding is provided by Congress to the Department of State (State) (52%), which advances U.S. objectives and interests worldwide through developing and implementing the President’s foreign policy; followed by the U.S. Agency for International Development (USAID) (33%), which supports long-term and broad-based economic growth in countries and advances U.S. foreign policy objectives; National Institutes of Health (NIH) (7%), which conducts biomedical and behavioral science research and is one of the world’s leading research entities on global health; and Centers for Disease Control and Prevention (CDC) (6%), which focuses on disease control and prevention and health promotion. In addition, a small portion (2.5%) of global health funding is channeled through the Department of Defense (DoD) (see Figure 3).

Figure 3

As mentioned earlier, most global health funding amounts are specified by Congress in annual appropriations bills, though some amounts are determined at the agency-level (see Table 2). State and USAID funding is provided in the State, Foreign Operations and Related Programs (SFOPs) appropriations bill; CDC and NIH funding is provided in the Labor, Health and Human Services (Labor HHS) appropriations bill, and DoD funding is provided in the Department of Defense appropriations bills. Within these bills, Congress specifies funding levels for global health program areas (e.g. HIV, TB, MCH, GHS, etc.) under the Global Health Programs (GHP), Contributions to International Organizations (CIO) and International Organizations and Programs (IO&P) accounts at USAID and State as well as for global health programs at CDC. Congress does not specify global health funding amounts under some accounts at USAID²  and some amounts³  at NIH and DoD, and instead provides this authority to the administration.

5. Global health funding has been mostly flat for more than a decade with some exceptions, including increases in some years to respond to outbreaks and for some program areas.

The U.S. investment in global health grew significantly in the early 2000s, in large part because of the creation of major global health organizations and initiatives like the Global Fund in 2001 and PEPFAR in 2003. However, funding has been relatively flat since 2010, with spikes in some years due to the U.S. emergency response to disease outbreaks. U.S. global health funding is comprised of funding provided through the regular appropriations process, with additional funding provided some years through emergency supplemental funding for disease outbreaks, such as Ebola (FY 2015), Zika (FY 2017), and COVID-19 (FY 2020-2021). All additional funding provided through emergency supplemental appropriations must be approved by Congress, and this funding is on top of any regularly appropriated funding. Overall, global health funding reached its highest level to date in FY 2021, largely due to the U.S. global response to the COVID-19 pandemic (that year, emergency funding represented 45% of U.S. global health funding and regular appropriations accounted for 55%); without emergency funding, the high point was in FY 2023 ($12.9 billion). In FY 2025, global health funding was provided through a continuing resolution (CR) which maintained the prior year (FY 2024) amount of $12.4 billion (see Figure 4).

Figure 4

6. Bilateral HIV accounts for the largest share (nearly 50% through regular appropriations) of U.S. global health funding.

The majority of U.S. global health funding is provided for specific areas including bilateral HIV or PEPFAR, tuberculosis, malaria or PMI, maternal and child health, nutrition, family planning and reproductive health, neglected tropical disease, and global health security (see Table 3), with some additional funding provided for other efforts including contributions to the World Health Organization (WHO) and Pan American Health Organization (PAHO).⁴ 

Since FY 2006, most U.S. global health funding over time through regular appropriations has been directed to bilateral HIV programs, accounting for approximately 50% of U.S. global health funding in most years (see Figure 5). The Global Fund (learn more about the Global Fund in the multilateral discussion below) accounted for the next largest share over the period, followed by maternal and child health and malaria. More recently, the U.S. has emphasized global health security more, with funding for these efforts increasing considerably during the COVID-19 pandemic and afterward. Consistent with this trend, in FY 2025, the latest year of data available, most funding was provided to HIV efforts ($5.4 billion or 44%), followed by the Global Fund ($1.7 billion or 13%) and maternal and child health and global health security (both $1.3 billion or 10%) (see Figure 6). These shares may differ during times of emergency, when significant funds have been provided on a one-time basis to address emerging outbreaks.⁵ 

Figure 5

Figure 6

7. Most U.S. global health funding (approximately 80%) is for bilateral programs reaching almost 80 countries in six regions.

In FY 2023, the most recent year country-specific amounts are available, 81% of U.S. global health funding was provided bilaterally (country-to-country, directly funding implementation of global health activities in partner countries) spanning six regions (see Figure 7). While this funding was directed to almost 80 countries, with additional countries receiving support through U.S. regional programs and contributions to multilateral organizations, ten countries accounted for almost 60% of U.S. bilateral support for global health (Figure 8).

Looking by region, most U.S. bilateral support for global health programs in FY 2023 was provided in sub-Saharan Africa (84%), followed by South and Centra Asia (5%) and the Western Hemisphere (4%) (Figure 9). Looking by income, the majority (88%) of U.S. funding for global health was provided to low and lower-middle-income countries (46% and 42% respectively) (see Figure 10).

Figure 7

Figure 8

Figure 9

Figure 10

8. Approximately a fifth of U.S. global health funding supports multilateral organizations.

While the majority of U.S. funding for global health is provided bilaterally (81%), the U.S. has a long history of engagement with multilateral health organizations, which pool support from multiple countries for one or more areas of global health, and provides about a fifth (19%) of its global health funding to support⁶  these institutions (see Figure 10). Multilateral initiatives complement U.S. bilateral global health efforts, helping make progress toward U.S. goals in various program areas, and in some cases, multilateral support allows the U.S. to reach a larger number of countries.

As mentioned earlier, multilateral health institutions the U.S. supports include the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund), Gavi the Vaccine Alliance (Gavi), United Nations Children’s Fund (UNICEF), World Health Organization (WHO), Pan American Health Organization (PAHO), Joint United Nations Programme on HIV/AIDS (UNAIDS), United Nations Population Fund (UNFPA), TB Drug Global Drug Facility, and the Pandemic Fund (see Table 4). The Global Fund is the largest multilateral recipient by far of U.S. global health funding followed by Gavi (see Figure 11).

The U.S. provides funding to these organizations every year, with the exception of UNFPA due to ongoing political debates about abortion and the invocation of the Kemp-Kasten Amendment, which has been used by the President to prohibit funding to UNFPA in some years (see the KFF Kemp-Kasten explainer for more detail). During its first term, the Trump Administration also temporarily suspended funding to the WHO in 2020, though these actions were reversed by the Biden Administration in 2021 and the funding was ultimately provided. Most recently in 2025, as one of the first actions taken during its second term, the Trump Administration issued an executive order to formally withdraw from the WHO and suspend funding. In addition, the Pandemic Fund, a newer multilateral financing mechanism launched in 2022 aimed at helping countries build their capacity to prevent, prepare for, and respond to epidemics and pandemics, has not received funding from the U.S. since 2022. However, Congress has included provisions in recent appropriations bills to transfer up to a certain amount of global health funding toward the entity if a public health emergency arises.

Nevertheless, the U.S. is often the largest or one of the largest donors to multilateral health efforts. For example, compared to other donors, the U.S. ranks first in donor support to the Pandemic Fund (accounting for 41% of its funding), the WHO (accounting for 14% of its funding), and the Global Fund (accounting for 33% of its funding) and third in donor support to Gavi (accounting for 13% of its funding). In 2025, several of these multilateral health institutions will have replenishment conferences where the U.S. and other donors will pledge their support for the next funding cycle (see the KFF tracker on U.S. support to four multilateral health institutions).

Figure 11

9. The U.S. provides over 40% of total donor government assistance for global health.

The U.S. plays an integral role in international assistance for health and provides support for global health in the form of Official Development Assistance (ODA) for health. ODA is financial support from donor governments to low- and middle-income countries for areas such as economic development, health, education, governance, or infrastructure, which is provided both bilaterally and through multilateral organizations. The U.S. is the largest donor to global health, providing 42% of all international health assistance among major donor governments (see Figure 12).⁷  In addition, the U.S. has historically devoted a larger share of its foreign assistance to health than any other donor government, contributing almost 30% of its foreign assistance to global health in 2023 (see Figure 13).

Figure 12

Figure 13

10. Congress and the Administration can place requirements and/or restrictions on U.S. global health funding.

Congress: In addition to specifying funding levels for global health programs, Congress can also specify statutory requirements and policy provisions that:

• direct how funds are spent,
• determine which organizations receive funding, and
• shape the implementation and scope of global health activities.

For instance, one statutory requirement that directs how U.S. foreign assistance, including global health funding, is spent is the Helms Amendment, which prohibits the use of foreign assistance to pay for the performance of abortion as a method of family planning or to motivate or coerce any person to practice abortion. In terms of more general global health policy provisions included in appropriations bills, an example of a common provision is one that directs agencies to provide reports to Congress on certain program areas. A more recent policy provision included in the FY 2024 appropriations bill was a one-year reauthorization of PEPFAR.

Administration: The administration can also place requirements and restrictions on global health funding. For instance, starting with the Reagan administration, the “Mexico City Policy” (MCP)⁸  has required foreign NGOs to certify that they will not “perform or actively promote abortion as a method of family planning” using funds from any source (including non-U.S. funds) as a condition of receiving U.S. global health assistance. It has been instituted and rescinded along party lines, and expanded over time, by executive action shortly after a new administration takes office. More recently, the Trump administration issued an executive order initiating the U.S. withdrawal from the World Health Organization (WHO) and halting all funding to the multilateral organization.

1. As opposed to mandatory funding, which is funding that is dictated and set by law. Mandatory spending, which includes funding for entitlement programs such as Social Security, Medicare, Medicaid, and veteran’s programs, remains essentially unchanged from year to year, as funding levels for these programs are set by the laws that authorize and govern them. ↩︎
2. Congress specifies some Economic Support Fund (ESF) funding amounts at USAID (i.e. funding for family planning and reproductive health through the ESF account is often specified by Congress but funding for HIV through this account is not specified by Congress) and does not specify funding amounts for the Assistance for Europe, Eurasia and Central Asia (AEECA), Development Assistance (DA), and CIO accounts at USAID. ↩︎
3. Congress specifies some funding amounts for NIH and DoD in annual appropriations bills, including funding for the Fogarty International Center (FIC) at NIH and funding for global HIV at DoD. ↩︎
4. Areas that receive global health funding and are not a part of the key program areas listed were combined into an “other” category. “Other” includes U.S. contributions to the World Health Organization (WHO) and Pan American Health Organization (PAHO), as well as funding for the Emergency Reserve Fund, which was created in the FY 2017 Omnibus bill to respond to contagious infectious disease outbreaks and would be made available if there is an “emerging health threat that poses severe threats to human health.” It also includes funding for “other public health threats,” which includes funding for health activities that are not consistently a line item within the U.S. budget (for example, in the FY 2024 budget, the U.S. provided funding to cross-cutting health activities through the Health Reserve Fund and to the global health workforce through the Global Health Workforce Initiative). ↩︎
5. In the years where emergency supplemental funding for disease outbreaks has been provided, funding has gone to general global health activities, though sometimes funding is provided for specific global health programs including bilateral HIV (i.e. through emergency COVID-19 funding in FY 2021), the Global Fund (i.e. through emergency COVID-19 funding in FY 2021), and global health security (i.e. through emergency Ebola funding in FY 2015, FY 2018, and FY 2019; emergency Zika funding in FY 2016; and emergency COVID-19 funding in FY 2021). ↩︎
6. Represents “assessed” or “core” funding— funding that is specified by Congress and generally used to support essential functions and operations. The U.S. also provides funding to multilateral organizations through “voluntary” or “non-core” contributions—funding that is used for specific projects or initiatives the U.S. seeks to support. Unlike core funding, non-core funding is not specified by Congress in annual appropriations bills. ↩︎
7. Totals are based on Official Development Assistance (ODA) amounts as reported by donor governments to the Organisation for Economic Co-operation and Development (OECD) and include bilateral disbursements for health as well as the health-adjusted share of core contributions to multilateral organizations. Bilateral health amounts are based on three OECD sectors from the Credit Reporting System (CRS) database: (1) Health; (2) Population Policies & Programs and Reproductive Health (includes HIV/AIDS & STDs); and (3) Other Social Infrastructure and Services – Social Mitigation of HIV/AIDS. The health-adjusted share of donor government core contributions to multilateral organizations is calculated by applying the health share of a multilateral organization’s total disbursements (as reported in the CRS database) to the donor government’s core contribution for that multilateral organization (as reported in the OECD’s “Member use of the multilateral system” database). ↩︎
8. The Mexico City Policy was renamed “Protecting Life in Global Health Assistance” by President Trump during his first term. ↩︎

Planned Parenthood clinics have provided sexual and reproductive health services across the country since 1916 and currently serve over 2 million patients a year through close to 600 clinics across the United States. In many communities Planned Parenthood is the only clinic offering reproductive health care, including contraception, sexually transmitted infection testing and treatment, abortion services, pregnancy testing, cancer screenings like Pap smears and breast exams, and other preventive services. One third of Planned Parenthood’s revenue comes from state and federal government funding, including Medicaid, to provide health care services. According to Planned Parenthood’s 2022-2023 Annual Report, abortion services make up 4% of all the health services they provide, and federal funds rarely go toward abortion care (only in cases of rape, incest and life-threatening situations). The vast majority of the state and federal funding goes to reimburse reproductive and preventive services. “Defunding” Planned Parenthood has long been a priority of Republican leadership at both state and federal levels and was highlighted as a priority in Project 2025. There are currently multiple efforts at the federal and state level to limit funding to Planned Parenthood.

According to newly released KFF Health Tracking Poll data, one in three women (32%) say they have gone to a Planned Parenthood clinic for care, as well as one in ten men (11%) (Figure 1). Nearly half of Black women have gone to a Planned Parenthood clinic. Over four in ten individuals with Medicaid say they have received services at Planned Parenthood and one third of those with private insurance. One in five Republican women and four in ten Democratic women have received care at a Planned Parenthood clinic.

There are currently three major efforts underway to cut funding to Planned Parenthood that could result in major reductions in services and staff, and ultimately, could result in clinic closures.

1. Medicaid

There have been efforts by anti-abortion groups and policymakers to exclude Planned Parenthood clinics from participating in the Medicaid program for many years because of their involvement in the provision of abortion services, even though federal funds cannot be used to pay for abortion services outside of cases of rape, incest, and life endangerment. KFF analysis shows that in 2021, one in 10 women on Medicaid who obtained family planning services got their care at Planned Parenthood. The share ranges from three in ten women with Medicaid in California (29%), to no women in in North Dakota and Wyoming where Planned Parenthood does not have a presence. Among the Medicaid patients who used Planned Parenthood for their family planning care, 85% obtained contraceptive services and about half got STI and/or gynecological care (Figure 2).

Republicans in Congress are currently considering a reconciliation financing bill that would ban federal Medicaid payments to Planned Parenthood and other Medicaid essential community providers across the country for services they provide to Medicaid beneficiaries. The Congressional Budget Office estimates that this will increase federal Medicaid spending by $300 million over ten years. In 2017, when Republicans were in the majority, they made a similar attempt to exclude Planned Parenthood from Medicaid via the reconciliation bill to repeal and replace the Affordable Care Act. While that bill did not pass, it would have cut off all federal payments to Planned Parenthood, including Medicaid reimbursement for contraceptive, STI, and preventive care for one year. The network of safety net providers, including health centers, health departments, and outpatient hospital sites likely would not have had the capacity to fully absorb the loss of Planned Parenthood in many communities in 2017, nor would they today. Prior research in Texas found that removing Planned Parenthood from the Texas family planning waiver program resulted in reduced contraceptive continuation and an increase in Medicaid covered births.

Several states have also attempted to exclude Planned Parenthood from their state Medicaid programs. Texas eventually terminated Planned Parenthood from its full-scope Medicaid program in 2021, and other states (South Carolina, Idaho, Tennessee) also have pending Section 1115 waiver applications at Centers for Medicare & Medicaid Services that would allow them to do the same. The Supreme Court is currently considering a case about South Carolina’s efforts to exclude Planned Parenthood from participating in their state’s Medicaid program and whether Medicaid beneficiaries can sue if they cannot freely choose their provider so long as they are willing and qualified to provide care, which is one of the federal provisions of the Medicaid law. The Supreme Court will likely rule on this in June and if the court rules in favor of South Carolina, states will have greater latitude to exclude Planned Parenthood from their Medicaid program.

2. Title X

The Trump Administration is currently withholding Title X funds from all nine of the Planned Parenthood grantees in the Title X program, which amounts to $20.6 million to provide services to low-income and uninsured people, saying the grantees are not aligned with the president’s opposition to Diversity, Equity, and Inclusion. In addition, other grantees that include Planned Parenthood clinics in their networks have received notices that that their funding is being withheld. Altogether, 144 Planned Parenthood clinics in 20 states are affected by the Title X decision to withhold funding (Figure 3).

Figure 3

While Title X makes up a smaller share of funding that supports services at Planned Parenthood clinics compared to Medicaid, these funds enable clinics to provide free and low-cost contraceptive methods, STI testing and treatment, pregnancy tests, cancer screenings like Pap smears and breast exams, and other preventive services. Already, two Planned Parenthood clinics in Utah and four Planned Parenthood clinics in Michigan have announced they will close due to Title X funds being withheld.

President Trump’s budget proposes terminating the $286 million appropriation for the Title X program. Furthermore, Project 2025 calls for reinstating the Title X regulations from the first Trump Administration that prohibited clinics from participating in the program if they had co-located abortion services or provided abortion referrals. This blocked 410 Planned Parenthood clinics from participating in Title X funding until the Biden Administration reversed the Trump Administration regulations.

3. Teen Pregnancy Prevention

Six Planned Parenthood affiliates receive funds from the Federal Teen Pregnancy Prevention (TPP) program to implement programs and develop, test, and evaluate innovative approaches to prevent teen pregnancy across the United States. These grantees, funded in 2023, have received $5.6 million annually to reach populations with the greatest unmet need with the goal of improving the optimal health of adolescents and reducing teen pregnancies and sexually transmitted infections.

On March 31, 2025, the TPP grantees were notified that the continuation applications due on April 15, 2025, would require them to demonstrate alignment with current Presidential Executive Orders, many of which are in direct conflict with the content in the evidence-based programs the grantees are funded to implement. This includes Executive Orders that ban the promotion of racial equity and gender inclusivity, current tenets of the TPP program (and also the care provided by family planning clinics). The funding opportunity the grantees applied under was called “Advancing Equity in Adolescent Health through Evidence-Based Teen Pregnancy Prevention Programs and Services” and applicants had to demonstrate as part of their grant application the extent to which they were committed to advancing health equity. Five of the six Planned Parenthood TPP grantees have filed a lawsuit against the Trump administration asking the Court to set aside the new alignment requirements and order HHS to allow grantees to continue receiving funding under the initial grant agreement. President Trump’s budget also proposes eliminating the Teen Pregnancy Prevention program along with Title X.

Note: Originally published on October 2, 2024, this resource is updated as needed, most recently on May 14, 2025, to reflect additional developments.

There have or will be several resource mobilization efforts for multilateral health organizations in 2024 and 2025. These include: the Pandemic Fund’s first pledging event; the World Health Organization’s (WHO) first investment round; Gavi, the Vaccine Alliance’s (Gavi) fourth replenishment; and the Global Fund to Fight AIDS, Tuberculosis and Malaria’s (Global Fund) eighth replenishment. The U.S. is the largest contributor to global health and has played an integral role in each of these four organizations, and while pledging events represent commitments rather than immediate transactions, as U.S. funding must be approved by Congress, these events will nevertheless signal future U.S. support to these entities and to global health more broadly. This KFF tracker provides up to date information on U.S. pledges thus far to these four multilateral health replenishments and U.S. government support to date for these entities.

National opioid overdose deaths have declined since mid-2023 and provisional 2024 data suggest the decline is continuing. Despite recent improvements, opioids were still involved in over 79,000 deaths in 2023—well above pre-epidemic levels. The opioid epidemic’s impact remains widespread with nearly three in ten adults (29%) reporting in a 2023 KFF poll that they or a family member experienced an opioid addiction.

Medicaid provided coverage to nearly half (47%) of all nonelderly adults with opioid use disorder (OUD) in 2023, according to data from the National Survey on Drug Use and Health (NSDUH). State-level NSDUH data from 2021-2022 show even higher Medicaid coverage rates among adults with OUD in states that expanded Medicaid under the Affordable Care Act (ACA). In recent years, state Medicaid programs have also expanded access to OUD treatment and medications, which reduce the risk of overdose death.

The Trump administration’s opioid policies emphasize expanding access to medication treatment and naloxone. At the same time, the House and Senate are working on legislation to meet the requirements in the budget resolution, specifying cuts to Medicaid of up to $880 billion or more over 10 years. To meet the required federal budget cuts, a newly introduced House bill proposes a number of provisions that could affect Medicaid eligibility and coverage stability for adults with OUD including work requirements and increased eligibility determinations. Such changes would contribute to reductions in Medicaid enrollment and increases in the uninsured and would come at a tenuous moment for the opioid epidemic, as deaths have begun to decline, but future progress is not certain. Amid this evolving policy landscape, this brief analyzes Medicaid coverage and treatment of adults with OUD using data from NSDUH and Medicaid claims data.

Medicaid is the main source of coverage for adults with opioid use disorder and among those receiving treatment services.

Medicaid covers 47% of all nonelderly adults with OUD and is the primary coverage source among those receiving treatment services. Specifically, Medicaid covers over half (56%) of those receiving medication for opioid use disorder (MOUD) and roughly two-thirds (64%) of adults receiving outpatient treatment and peer support services (Figure 1). MOUD treatment, recommended by clinical guidelines, reduces risk of all-cause and overdose mortality.

Most adults with OUD in Medicaid are eligible through Medicaid expansion.

Overall, 61% of adult Medicaid enrollees diagnosed with OUD—about 900,000 adults—are eligible through Medicaid expansion (Figure 2), with state-level rates ranging from 33% in Arkansas to 95% in Illinois (Appendix Table 1). In expansion states, over two-thirds of Medicaid enrollees with OUD qualify through ACA expansion (Figure 2), facilitating access to medication treatment and other care. A number of provisions in the House bill would affect the expansion group, including work requirements and cost sharing requirements. Such changes could lead to coverage losses or disruptions, including for adults with OUD, potentially limiting or interrupting access to treatment. Research indicates that MOUD treatment cessation is linked to significantly increased mortality risk, with individuals experiencing a six-fold higher mortality risk in the four weeks immediately after discontinuing treatment.

Other federal actions may also affect opioid response efforts.

The restructuring of Health and Human Services (HHS) by the Trump administration folds the Substance Abuse and Mental Health Services Administration (SAMHSA) into a new agency, reduces staff, and may eliminate certain opioid-focused programs. Additionally, the reported dismissal of the entire staff administering the NSDUH—a key source of national data collecting data for over 50 years about trends in mental health and substance use disorders—-could limit access to key data used to monitor and respond to the opioid crisis. The President’s discretionary budget request for 2026–which has not been adopted to date–proposes just over $1 billion in cuts to SAMHSA programs, including cuts to programs funding clean syringe exchanges and safe supplies. The discretionary budget decisions will be part of the budget appropriations process.

Note: This fact sheet largely reflects activities prior to the second Trump administration, which has issued numerous executive actions that directly affect global health efforts, and has been updated to highlight key recent actions that may affect PMI and other U.S. global malaria efforts. See also the KFF fact sheet on the Trump administration’s foreign aid review and the status of PMI.

Key Facts

• About half of the world’s population is at risk of being infected with malaria. In 2023, there were an estimated 263 million cases of malaria and 597,000 deaths from malaria worldwide. Sub-Saharan Africa is the hardest hit region in the world.
• While gains have been made over the past two decades in increasing access to malaria prevention and treatment, many challenges (including drug and insecticide resistance and climate change impacts) continue to complicate malaria control efforts in hard-hit areas. Recently, in promising developments, the first malaria vaccine was recommended in 2021 by the World Health Organization (WHO) for widespread use in children, and its broader rollout began in 2023. Additionally, in late 2023, WHO recommended a second malaria vaccine. These vaccines are now being rolled-out across Africa in routine childhood immunization programs.
• The U.S. government (U.S.) has been involved in global malaria activities since the 1950s and, today, is the largest donor government to global malaria efforts.
• U.S. malaria efforts include activities primarily through the U.S. President’s Malaria Initiative (PMI) that is overseen by the U.S. Global Malaria Coordinator, as well as through other U.S. activities; collectively, the U.S. reaches approximately 30 countries.
• U.S. funding for malaria control efforts and research activities was approximately $1 billion in FY 2025, up from $873 million in FY 2016. Additionally, the U.S. is the largest donor to the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund), which in turn is the largest overall funder of malaria efforts in the world.
• As the Trump administration reorganizes foreign assistance (and Congress considers whether to approve these changes), including dissolving the U.S. Agency for International Development (USAID) – the lead implementer of PMI, its impact on the future of U.S. global malaria efforts remains to be seen.

Global Situation¹ 

Malaria is one of the world’s most common and serious tropical diseases, with about half the world’s population at risk of being infected with malaria. Although preventable and treatable, malaria causes significant morbidity and mortality, with the greatest numbers of cases and deaths in resource-poor regions and among young children.² 

Strategies and efforts to address malaria have evolved over time, with global eradication efforts waning in the 1970s, resulting in rising rates.⁴  In the late 1990s, malaria began to receive renewed attention, particularly after the 1998 creation of the Roll Back Malaria Partnership (RBM), now referred to as the RBM Partnership to End Malaria.⁵  In 2000, all nations agreed to global malaria targets as part of Millennium Development Goal 6 (combat HIV/AIDS, malaria, and other diseases). Since then, expanded efforts by the U.S. government, other donor governments, multilateral institutions, and affected countries have helped to increase access to malaria prevention and treatment and reduce cases and deaths, and there has been, at times, discussion of the possibility of finally eradicating the disease.⁶ 

Today global malaria activities are focused on sustaining, improving, and expanding efforts to control the disease. Still, the rate of progress has stalled in some countries recently, and many challenges continue to complicate malaria control efforts in countries with ongoing malaria transmission, including poverty, poor sanitation, weak health systems, limited disease surveillance capabilities, natural disasters, armed conflict, migration, climate change, and the presence of counterfeit and/or sub-standard antimalarial drugs.⁷ 

Morbidity and Mortality⁸ 

• WHO estimates that there were approximately 263 million cases of malaria and 597,000 deaths, mostly among children under the age of five, in 2023. Overall, substantial scale-up of malaria interventions helped reduce the malaria case incidence and death rates over the past two decades, though case incident rates were slightly higher in 2023 than in 2022 due to increased rates in some countries.
• Multidrug-resistant malaria is a widespread and recurring problem, and while highly-effective artemisinin-based combination therapies (ACTs) have been introduced to treat drug-resistant strains, evidence suggests ACT resistance is occurring in parts of Asia and Africa.⁹  Resistance to insecticides has emerged as a problem in Africa, the Americas, Eastern Mediterranean, South-East Asia, and the Western Pacific.¹⁰ 
• Certain groups, particularly pregnant women and children, are more vulnerable. Making up 76% of all malaria deaths in the Africa region, children under five are especially at-risk of malaria infection, because they lack developed immune systems to protect against the disease. Other high-risk groups include people living with HIV/AIDS, travelers, refugees, displaced persons, and migrant workers entering endemic areas.

Interventions

Malaria control efforts involve a combination of prevention and treatment strategies and tools, such as:

• insecticide-treated bed nets (ITNs),¹¹ 
• indoor residual spraying (IRS) with insecticides,
• diagnosis and treatment with antimalarial drugs, particularly artemisinin-based combination therapies (ACTs),¹² 
• intermittent preventive treatment in pregnancy (IPTp, a drug treatment for pregnant women that prevents complications from malaria for a woman and her unborn child),
• perennial malaria chemoprevention (PMC, formerly called intermittent preventive treatment in infants (IPTi), a drug treatment aimed at reducing adverse effects of malaria in children belonging to age groups at high risk of severe malaria), and
• seasonal malaria chemoprevention (SMC, a treatment course administered at monthly intervals to children belonging to age groups at high risk of severe malaria during the high malaria transmission season).

More recently, in 2021, WHO recommended, and in 2022 prequalified, the first malaria vaccine (RTS,S/AS01 or RTS,S) and in 2023 recommended and prequalified a second malaria vaccine (R21/Matrix-M or R21), both of which have been shown to be safe and effective in preventing malaria in children during clinical trials.¹³  As of December 2024, 17 countries that represent approximately 70% of the global malaria burden offered these vaccines through routine childhood immunization programs, and more are planning to introduce or scale them up.¹⁴  Roll-out of these vaccines will depend on financing and country decisions about whether to adopt the vaccines as part of their national malaria control strategies, among other things.

Access to prevention and treatment services has grown over time, as ITN coverage has increased and the number of ACT treatments procured by the public and private sectors has expanded substantially.¹⁵ 

Global Goals

Since the late 1990s, new initiatives and financing mechanisms have helped increase attention to malaria and contributed to efforts to achieve global goals; these include the RBM Partnership to End Malaria, a global framework established in 1998 for coordinating malaria efforts among donor governments, major UN agencies, international organizations, and affected countries, among others; and the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund), an independent, international financing institution established in 2001 that provides grants to countries to address TB, HIV, and malaria (see the KFF fact sheet on the U.S. and the Global Fund).¹⁶ 

These and other efforts work toward achieving major global malaria goals that have been set through:

• Sustainable Development Goals (SDGs). Adopted in 2015, the SDGs aim to end the malaria epidemic by 2030 under SDG Goal 3, which is to “ensure healthy lives and promote well-being for all at all ages.”¹⁷ 
• Global Technical Strategy for Malaria (GTS). Developed in close alignment with the RBM Partnership and adopted by the World Health Assembly in 2015, the GTS includes the goals of reducing malaria incidence and mortality rates by at least 90% by 2030, eliminating the disease in at least 35 new countries, and preventing the disease’s re-establishment in countries that are malaria free.

With these goals, the GTS sets out a vision for countries to accelerate progress towards malaria elimination, and globally, more countries are moving towards elimination. Since 2000, 26 countries (Algeria, Argentina, Armenia, Azerbaijan, Belize, Cabo Verde, China, Egypt, El Salvador, Georgia, Iran, Iraq, Kazakhstan, Kyrgyzstan, Malaysia, Maldives, Morocco, Oman, Paraguay, Sri Lanka, Syrian Arab Republic, Tajikistan, Turkey, Turkmenistan, United Arab Emirates, and Uzbekistan) have attained three consecutive years of zero indigenous malaria cases and are therefore recognized as having eliminated the disease.¹⁸  In 2023, of 83 malaria-endemic countries, 47 countries worldwide were reported to have been nearing elimination.¹⁹  Most recently, in March 2024, WHO along with Ministers of Health in Africa and other partners convened a Malaria Ministerial Conference and signed a declaration committing to accelerating action to end deaths from malaria.²⁰ 

The U.S. Government

Involved in global malaria activities since the 1950s, the U.S. government (U.S.) is the largest government donor to malaria efforts.²¹  It is also the largest donor to the Global Fund, which in turn is the largest overall funder of malaria efforts in the world.²² 

History

The U.S. government’s international response to malaria began in the 1950s through activities at the U.S. Centers for Disease Control and Prevention (CDC) and U.S. Agency for International Development (USAID); early efforts focused on technical assistance but also included some direct financial support for programs overseas.

Since the early 2000s, the U.S. has assigned a heightened priority to and provided greater funding for bilateral and multilateral malaria efforts. In 2003, the U.S. Leadership Against HIV/AIDS, Tuberculosis, and Malaria Act of 2003 (the legislation that created PEPFAR, the expanded U.S. government response to global AIDS) authorized five years of funding for bilateral malaria efforts and the Global Fund. In 2005, the U.S. launched the President’s Malaria Initiative (PMI), a five-year effort to address malaria in 15 hard-hit African countries, which has since been extended and expanded. In 2008, the Lantos-Hyde U.S. Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008 (which reauthorized PEPFAR) authorized another five years of funding and codified the position of the U.S. Global Malaria Coordinator.²³  More recently, in 2021, the U.S. released its PMI strategy for 2021-2026, which outlines its goals as well as its approach to achieving them by 2026.²⁴  (See the KFF fact sheet on PEPFAR, the KFF fact sheet on the Global Fund, the KFF brief on PEPFAR reauthorization legislation, and the KFF dashboard monitoring progress toward global malaria targets in PMI countries.)

Organization and Goals

President’s Malaria Initiative (PMI)²⁵ 

Launched in 2005, the President’s Malaria Initiative (PMI) is an interagency initiative to address global malaria that was, until its recent dissolution, led by USAID and implemented in partnership with CDC. It is overseen by the U.S. Global Malaria Coordinator, who is appointed by the President and reports to the USAID Administrator, and an Interagency Advisory Group made up of representatives from USAID, CDC, the National Institutes of Health (NIH), the Department of Defense (DoD), the State Department, the Peace Corps, the National Security Council, and other U.S. government agencies.²⁶  USAID has served as the lead implementing agency for U.S. global malaria efforts, primarily through PMI, with other agencies also carrying out malaria activities. Collectively, prior to the second Trump administration, U.S. bilateral activities reached approximately 30 countries.²⁷  Now, as the Trump administration reorganizes foreign assistance (and Congress considers whether to approve these changes), having dissolved USAID, it is unclear whether it will integrate any remaining USAID global health activities, including PMI, into the State Department, and what the future holds for PMI. See the KFF fact sheet on the status of malaria efforts.

Goals

In 2021, the U.S. released the President’s Malaria Initiative Strategy 2021-2026; its goals include:

• reducing malaria mortality by one-third from 2015 levels in high-burden PMI-supported countries, ²⁸ 
• achieving a greater than 80% reduction from PMI’s original 2000 baseline levels,
• reducing malaria morbidity in PMI-supported countries with high and moderate malaria burden by 40% from 2015 levels,²⁹  and
• assisting at least ten PMI-supported countries to meet the WHO criteria for national or sub-national elimination and at least one country in the Greater Mekong subregion to reach national elimination.

The strategy also states that these efforts contribute to longer term goals, such as elimination of malaria in a growing number of countries, and aligns with global priorities.³⁰ 

Key Activities³¹ 

Prior to the current administration, PMI activities focused on expanding access to and the use of six key malaria control interventions: insecticide-treated bed nets (ITNs), indoor residual spraying (IRS) with insecticides, entomological monitoring, intermittent preventive treatment in pregnancy (IPTp),³²  diagnosis of malaria and treatment with artemisinin-based combination therapies (ACTs), and seasonal malaria chemoprevention (SMC).³³ 

They also included a range of malaria control activities, including technical assistance to affected countries, monitoring and evaluation, supply chain management, and commodity procurement (since the start of PMI, U.S. support for commodities, such as ITNs, insecticides, and antimalarial drugs, like ACTs, has increased significantly³⁴ ). Additionally, PMI supported activities in the following areas: behavior change communication, health systems strengthening, monitoring and evaluation, operational research, elimination, and community health.³⁵ 

USAID had also supported regional efforts in Latin America and the Caribbean, including providing technical assistance to support countries in tailoring their approaches for malaria control through its Amazon Malaria Initiative.³⁶  CDC provided technical assistance to these regional efforts and was also designated as the WHO Collaborating Center for Prevention and Control of Malaria,³⁷  though with the Trump administration’s announcement that the U.S. would withdraw from WHO, the future of this partnership remains an open question. It also remains to be seen how recent announcements of global health reductions at CDC could further affect malaria efforts.

Additionally, NIH and DoD have been involved in malaria research and development (R&D). NIH is the lead agency for U.S. malaria R&D efforts (including its International Centers of Excellence for Malaria Research program, which established a global network of malaria research centers in 2010 to support research activities in malaria-endemic countries).³⁸  DoD also supports extensive R&D efforts as well as worldwide malaria disease surveillance, and technical assistance and capacity building with local partners.³⁹   The future of U.S. support for these efforts is uncertain as the Trump administration reduces and eliminates foreign research grants.

Countries Reached

Prior to the current administration, PMI spanned 27 sub-Saharan African “focus countries” (gradually scaled up from three countries in FY 2006), as well as three countries in Southeast Asia under the PMI Greater Mekong Subregion regional initiative.⁴⁰  Focus countries were selected based on the following criteria:⁴¹ 

• high malaria burden,
• alignment of National Malaria Control Plan (NMCP) with WHO standards,
• country capacity to implement national control policies,
• willingness to partner with the US in fighting malaria, and
• involvement of other international donors (e.g., Global Fund; World Bank).

Both USAID and CDC stationed staff in each PMI focus country, though USAID staff are or have been recalled to the U.S. due to the Trump administration’s dissolution of USAID and reorganization of foreign assistance.

Beyond PMI, the Amazon Malaria Initiative spanned several countries in Latin America and the Caribbean, and other U.S. activities may reach more countries. For example, CDC and USAID have carried out activities in additional countries in sub-Saharan Africa, the Caribbean, and Asia.⁴² 

Multilateral Efforts

The U.S. partners with international institutions and supports global malaria funding mechanisms. Key partners include the World Health Organization (although the second Trump administration immediately announced the U.S. would withdraw as a member of and halt funding to WHO), the RBM Partnership, and the World Bank. Additionally, the U.S. government is the largest donor to the Global Fund, which has approved over $22 billion in funding for malaria programs worldwide and is the largest overall funder of global malaria efforts.⁴³ 

Funding⁴⁴ 

U.S. funding for malaria, which is specified by Congress in annual appropriations bills and includes support for PMI as well as other malaria control efforts and research activities, has increased over the past decade from $873 million in FY 2016 to approximately $1 billion in FY 2025; while funding increased over the period, it has been relatively flat in recent years (see figure for the latest information). Additional U.S. support for malaria activities is provided through its contribution to the Global Fund. (See the KFF fact sheet on the U.S. Global Health Budget: Malaria/PMI and the KFF budget tracker for more details on historical appropriations for U.S. global malaria efforts.)

Most U.S. bilateral funding for malaria has been provided through the Global Health Programs account at USAID with additional funding provided through NIH, CDC, and DoD. The majority of U.S. malaria funding has been directed to PMI focus countries, with additional funding directed to other bilateral and regional malaria efforts as well as malaria research activities.

1. WHO, World Malaria Report 2024, 2024. ↩︎
2. WHO, World Malaria Report 2024, 2024. WHO, “Malaria fact sheet,” webpage, Dec. 2024, https://www.who.int/en/news-room/fact-sheets/detail/malaria. ↩︎
3. CDC Malaria website, https://www.cdc.gov/malaria/hcp/clinical-features/ ↩︎
4. M. Tanner, D. de Savigny, “Malaria Eradication Back on the Table,” Bulletin of WHO, Vol. 86, No. 2, 2008. ↩︎
5. Launched by the World Health Organization, the United Nations Children’s Fund, the United Nations Development Programme, and the World Bank as “an effort to provide a coordinated global response to the disease.” RBM Partnership to End Malaria, “RBM Partnership to End Malaria Overview,” webpage, https://endmalaria.org/about-us/overview1. ↩︎
6. M. Tanner, D. de Savigny, “Malaria Eradication Back on the Table,” Bulletin of WHO, Vol. 86, No. 2, 2008; WHO, World Malaria Report 2024, 2024. ↩︎
7. WHO, World Malaria Report 2024, 2024; M. Tanner and D. de Savigny, “Malaria Eradication Back on the Table,” Bulletin of WHO, Vol. 86, No. 2, 2008; RBM, The Global Malaria Action Plan, 2008; K. Senior, “Climate Change and Infectious Disease: A Dangerous Liaison?”, The Lancet. Vol. 8, No. 2,  2008; CDC, “Preventing Malaria While Traveling,” webpage, https://www.cdc.gov/malaria/prevention/index.html. ↩︎
8. WHO, World Malaria Report 2024, 2024; WHO, “Malaria fact sheet,” webpage, Dec. 2024, https://www.who.int/en/news-room/fact-sheets/detail/malaria. ↩︎
9. WHO, World Malaria Report 2024, 2024; Global Plan for Artemisinin Resistance Containment (GPARC), 2011; Emergency Response to Artemisinin Resistance in the Greater Mekong Subregion: Regional Framework for Action 2013-2015, April 2013; Status report on artemisinin resistance and ACT efficacy, December 2019, accessed here: https://apo.who.int/publications/i/item/status-report-on-artemisinin-resistance-and-act-efficacy; “Malaria: Artemisinin partial resistance” webpage, https://www.who.int/news-room/questions-and-answers/item/artemisinin-resistance. WHO, Strategy to respond to antimalarial drug resistance in Africa, 2022. ↩︎
10. To address insecticide resistance, the WHO issued updated guidance in 2023 recommending the use of dual active ingredient ITNs. WHO, Press release: WHO publishes recommendations on two new types of insecticide-treated nets, March 2023. ↩︎
11. In 2023, WHO published recommendations on two new types of dual active ingredient insecticide-treated mosquito nets, designed to provide greater protection against malaria than previously recommended nets. WHO, World Malaria Report 2024, 2024. ↩︎
12. For a detailed description of WHO’s recommendations on the use of drugs to prevent malaria in high-risk groups, please see WHO’s Guidelines for Malaria. WHO, Guidelines for Malaria, March 2023. ↩︎
13. Vaccines that are added to WHO’s prequalification list are endorsed by WHO as having gone through comprehensive evaluation to determine that the vaccine is safe and effective. WHO, Press release: WHO recommends groundbreaking malaria vaccine for children at risk, October 2021. WHO, Press release: WHO recommends R21/Matrix-M vaccine for malaria prevention in updated advice on immunization, October 2023. WHO, Press release: WHO prequalifies a second malaria vaccine, a significant milestone in prevention of the disease, December 2023. ↩︎
14. WHO, Press release: Life-saving malaria vaccines reach children in 17 endemic countries in 2024, December 2024. ↩︎
15. WHO, Malaria Prevention Works: let’s close the gap, April 2017. WHO, World Malaria Report 2024, 2024. ↩︎
16. RBM Partnership to End Malaria website, https://endmalaria.org/; Global Fund website, https://www.theglobalfund.org/en/. ↩︎
17. UN, Transforming our world: the 2030 Agenda for Sustainable Development, 2015. ↩︎
18. WHO, World Malaria Report 2024, 2024. ↩︎
19. Countries that were malaria endemic in 2000 and reported fewer than 10,000 malaria cases are said to be “nearing elimination.” WHO, World Malaria Report 2024, 2024. ↩︎
20. WHO, Press release: African health ministers commit to end malaria deaths, March 2024. ↩︎
21. WHO, World Malaria Report 2024, 2024. ↩︎
22. KFF: Global Financing for Malaria: Trends & Future Status, 2014; Mapping the Donor Landscape in Global Health: Malaria, 2013; World Malaria Report 2024, 2024. KFF analysis of OECD DAC CRS database, February 2025. ↩︎
23. U.S. Congress, Public Law 108-25, May 27, 2003; U.S. Congress, Public Law 110-293, July 30, 2008. ↩︎
24. The PMI 2021-2026 strategy is an update to PMI’s 2015-2020 strategy. PMI, U.S. President’s Malaria Initiative Strategy 2021-2026, October 2021. ↩︎
25. PMI website, https://www.pmi.gov/; USAID, “The President’s Malaria Initiative,” fact sheet, May 2023; PMI, The President’s Malaria Initiative: Eighteenth Annual Report to Congress, 2024; PMI, FY 2017 Greater Mekong Subregion Malaria Operational Plan, 2017; CDC, “President’s Malaria Initiative,” webpage, https://www.cdc.gov/malaria/malaria_worldwide/cdc_activities/pmi.html. ↩︎
26. PMI. “Leadership” webpage, accessed: https://www.pmi.gov/about-us/#leadership. ↩︎
27. KFF analysis of data from the U.S. Foreign Assistance Dashboard website, www.foreignassistance.gov, accessed February 2025. PMI, Eighteenth Annual Report to Congress, 2024. CDC, “Malaria’s Global Malaria Activities” webpage, https://www.cdc.gov/malaria/malaria_worldwide/cdc_activities/index.html. ↩︎
28. The countries targeted by PMI that are considered high burden include Angola, Benin, Burkina Faso, Cameroon, Côte d’Ivoire, Democratic Republic of the Congo, Ghana, Guinea, Liberia, Mali, Mozambique, Niger, Nigeria, and Sierra Leone. PMI, President’s Malaria Initiative Strategy 2021-2026, 2021. ↩︎
29. The countries targeted by PMI that are considered moderate burden include Madagascar, Malawi, Tanzania, Uganda, and Zambia. PMI, President’s Malaria Initiative Strategy 2021-2026, 2021. ↩︎
30. PMI, President’s Malaria Initiative Strategy 2021-2026, 2021. ↩︎
31. PMI, “What We Do,” webpage, https://www.pmi.gov/what-we-do/. ↩︎
32. Another preventive treatment includes PMC in countries where that treatment is relevant. To date only Sierra Leone has prioritized PMC for PMI support in their NMCPs. PMI, President’s Malaria Initiative Technical FY 2024 Guidance. ↩︎
33.   SMC is only recommended for geographic regions where the malaria transmission season is four months or less. PMI, President’s Malaria Initiative Technical FY 2024 Guidance. ↩︎
34. PMI, “Malaria Operational Plans,” webpage, https://www.pmi.gov/resources/malaria-operational-plans-mops/. ↩︎
35. PMI, “What We Do,” webpage, https://www.pmi.gov/what-we-do/. ↩︎
36. USAID, “Malaria: Countries,” webpage, https://www.usaid.gov/global-health/health-areas/malaria/countries. CDC, “CDC’s Global Malaria Activities” webpage, https://www.cdc.gov/malaria/malaria_worldwide/cdc_activities/index.html. ↩︎
37. CDC, “CDC’s Malaria Program,” fact sheet, 2023. ↩︎
38. NIAID: “Malaria,” webpage, https://www.niaid.nih.gov/diseases-conditions/malaria; “International Centers of Excellence for Malaria Research (ICEMR),” webpage, https://www.niaid.nih.gov/research/excellence-malaria-research. ↩︎
39. KFF, The Department of Defense and Global Health: Infectious Disease Efforts, 2013. ↩︎
40. In September 2017, PMI announced the addition of five new focus countries, bringing the number of PMI programs to 24 in sub-Saharan Africa. PMI. Press release: PMI Launches and Expands in West and Central Africa, September 2017; In April 2023, PMI announced its intention to expand to three more sub-Saharan African countries, increasing the total number of partner countries reached to 30 (27 in Sub-Saharan Africa and 3 in the Greater Mekong Region); the three additional countries include Burundi, The Gambia, and Togo. PMI, U.S. President’s Malaria Initiative Announces Plans to Expand to New Partner Countries, April 2023; PMI, “Where We Work,” webpage, https://www.pmi.gov/where-we-work/. ↩︎
41. PMI, 2011 PMI Fifth Annual Report, April 2011. ↩︎
42. CDC, “CDC’s Global Malaria Activities,” webpage, https://www.cdc.gov/malaria/malaria_worldwide/cdc_activities/index.html. ↩︎
43. Global Fund, Global Fund Data Explorer: https://data.theglobalfund.org/; accessed October 2024. KFF analysis. ↩︎
44. KFF analysis of data from the Office of Management and Budget, Agency Congressional Budget Justifications, Congressional Appropriations Bills, and the U.S. Foreign Assistance Dashboard website, www.foreignassistance.gov. ↩︎

Note: This fact sheet largely reflects activities prior to the second Trump administration, which has issued numerous executive actions that directly affect global health efforts, and has been updated to highlight key recent actions that may affect PEPFAR. See also the KFF fact sheet on the Trump administration’s foreign aid review and the status of PEPFAR.

Key Facts

• Although the U.S. has been involved in efforts to address the global AIDS crisis since the mid-1980s, the creation of the President’s Emergency Plan for AIDS Relief (PEPFAR) in 2003 marked a significant increase in funding and attention to the epidemic. Now, 20 years in, PEPFAR reports saving an estimated 26 million lives and is currently providing HIV prevention and treatment services to millions.
• PEPFAR is the largest commitment by any nation to address a single disease in the world, credited with not only saving millions of lives but also helping to change the trajectory of the global HIV epidemic.
• PEPFAR funding is comprised of U.S. bilateral funding and U.S. contributions to multilateral organizations addressing HIV, primarily the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund).¹ 
• To date, U.S. funding for PEPFAR has totaled over $120 billion, growing from $1.9 billion in FY 2004 to $6.5 billion in FY 2025; FY 2025 funding, which Congress provided through a continuing resolution, includes $4.8 billion provided for bilateral HIV efforts and $1.7 billion for multilateral efforts ($50 million for UNAIDS and $1.65 billion for the Global Fund).² 
• PEPFAR has been reauthorized by Congress four times, most recently in March 2024 for one year. Although that authorization expired on March 25, 2025, PEPFAR is a permanent part of U.S. law and, other than a set of eight time-bound provisions, continues as long as Congress appropriates funding for the program.
• More broadly, PEPFAR is – for the first time in its two-decade history – facing significant challenges that could impede its ability to fulfill its mission. The Trump administration has instituted a review of all foreign assistance, including for PEPFAR, as well as a funding freeze. These actions have already resulted in significant disruption and limitation of PEPFAR’s scope and services, and it is unknown whether the administration will recommend further changes to PEPFAR and how or if Congress will respond to these recommendations.

Global Situation

HIV, the virus that causes AIDS (“acquired immunodeficiency syndrome” or Advanced HIV Disease), has become one of the world’s most serious health and development challenges. Today, there are approximately 39.9 million people living with HIV, and tens of millions of people have died of AIDS-related causes since the beginning of the epidemic (see the KFF fact sheet on the global HIV epidemic).³ 

U.S. Government Efforts

Although the U.S. has been involved in efforts to address the global HIV/AIDS crisis since the mid-1980s,⁴  the creation of the President’s Emergency Plan for AIDS Relief (PEPFAR) in 2003 marked a significant increase in funding and attention to the epidemic.⁵  PEPFAR, the U.S. government’s global effort to combat HIV and the largest global health program devoted to a single disease, is credited with saving millions of lives and helping to change the trajectory of the global HIV epidemic. It was announced in January 2003 during President George W. Bush’s State of the Union and authorized by Congress that same year through the Leadership Act (see Table 1). The Leadership Act governs PEPFAR’s HIV response, as well as U.S. participation in the Global Fund (an independent, international multilateral financing institution that provides grants to countries to address HIV, TB, and malaria) and bilateral assistance for TB and malaria programs.⁶  Congress has updated, extended, and made changes to the program through the Lantos-Hyde Act of 2008, the PEPFAR Stewardship Act of 2013, the PEPFAR Extension Act of 2018, and more recently, a short-term reauthorization of PEPFAR that extended certain timebound provisions through late March 2025, when they were allowed to lapse (see Table 1 and the KFF brief on PEPFAR reauthorization legislation over time). This short term reauthorization signaled a departure from the program’s long history of strong bipartisan support across multiple Congresses and administrations when, in an increasingly partisan environment, it was caught up in the broader U.S. political debate over abortion (see the KFF brief on PEPFAR’s short term reauthorization). This and other rapidly-evolving developments, including the Trump administration’s review of foreign assistance, has introduced significant uncertainty about PEPFAR’s future, including its reauthorization prospects, although PEPFAR is a permanent part of U.S. law and will continue as long as Congress continues to provide funding to it.

Organization

PEPFAR’s original authorization established new structures and authorities, consolidating all U.S. bilateral and multilateral activities and funding for global HIV/AIDS. Several U.S. agencies, host country governments, and other organizations are involved in implementation.⁷ 

PEPFAR is overseen by the U.S. Global AIDS Coordinator, who is appointed by the President, confirmed by the Senate, and reports directly to the Secretary of State, as established through PEPFAR’s authorizing legislation.⁸  The Coordinator holds the rank of Ambassador and leads the Office of the Global AIDS Coordinator (OGAC) at the Department of State.⁹  The Coordinator has primary responsibility for the oversight and coordination of all U.S. global HIV activities and funding across multiple U.S. implementing agencies and departments. In addition, the Coordinator serves as the U.S. Government’s board member to the Global Fund (the U.S. Government holds a permanent seat on the Global Fund’s Board). The Coordinator is dual-hatted as the U.S. Special Representative for Global Health Diplomacy and also leads the broader Bureau of Global Health Security and Diplomacy, which brings together PEPFAR with global health security and global health diplomacy functions.¹⁰  Currently, the President has not yet nominated a Coordinator and it is unclear when or whether someone will be nominated.

In addition to the Department of State, other implementing departments and agencies for HIV activities include: the U.S. Agency for International Development (USAID), PEPFAR’s largest government implementing agency (the Trump administration has moved to dissolve USAID, creating uncertainty about how PEPFAR’s implementation will be managed by the U.S. government going forward); the Department of Health and Human Services, primarily through the Centers for Disease Control and Prevention (CDC); the Departments of Labor, Commerce, and Defense (DoD); and the Peace Corps.¹¹  As the Trump administration continues its review of foreign assistance and pursues reorganization of global health programs, Congress has yet to weigh in and it is unclear what the future of PEPFAR will look like.

Key Activities and Results

PEPFAR reports saving an estimated 26 million lives and its activities have focused on expanding access to HIV prevention, treatment, and care interventions. These have included provision of antiretroviral treatment, pre-exposure prophylaxis, voluntary male circumcision, condoms, and other commodities related to HIV services (see Table 2).^12 ,13  In addition, PEPFAR has launched specific initiatives in key strategic areas. For example, in 2015, PEPFAR launched DREAMS, a public-private partnership that aims to reduce HIV infections in adolescent girls and young women.

The latest results reported by PEPFAR indicate that it has:

• supported testing services for 83.8 million people in FY 2024;
• prevented 7.8 million babies from being born with HIV, who would have otherwise been infected;
• provided care for more than 6.6 million orphans, vulnerable children (OVC), and their caregivers;
• supported training for nearly 342,000 new health care workers; and
• supported antiretroviral treatment for 20.6 million people.¹⁴ 

Additionally, it reports that PEPFAR reached 2.3 million adolescent girls and young women with HIV prevention services in FY 2024, and new diagnoses among this population have declined, with the higher rate of initiation of pre-exposure prophylaxis (PrEP) to prevent HIV infection in countries implementing the DREAMS initiative compared to areas without DREAMS programming.¹⁵  The Trump administration’s foreign aid review and funding freeze have limited PEPFAR’s activities to those defined in a limited waiver, significantly scaling back PEPFAR’s scope to what the waiver defines as “life-saving HIV services,” which include only certain activities: HIV treatment and care, prevention of mother-to-child transmission (PMTCT), pre-exposure prophylaxis (PrEP) for pregnant and breastfeeding women, and HIV testing.

Countries Reached

Historically, PEPFAR bilateral programs were carried out in more than 50 countries.¹⁶  Additional countries are reached through U.S. contributions to the Global Fund. PEPFAR currently requires 25 countries¹⁷  and the Asia, Western Hemisphere, and West Africa regional programs to develop “Country Operational Plans” (COPs) and “Regional Operational Plans” (ROPs), respectively, to document annual investments and anticipated results.¹⁸  OGAC reviews and the Global AIDS Coordinator approves COP/ROPs.

Funding¹⁹ 

Total PEPFAR funding²⁰  includes bilateral funding for HIV activities conducted by U.S. implementing agencies as well as U.S. contributions to the Global Fund and UNAIDS,²¹  as specified by Congress for PEPFAR in annual appropriations bills.²²  It represents the majority of U.S. global health funding (about 53% in recent years²³ ) and is the largest commitment by any nation to address a single disease in the world. To date, PEPFAR funding has totaled over $120 billion, with funding reaching $6.5 billion in FY 2025 (in FY 2025, PEFPAR funding was provided through a continuing resolution, which maintained the prior year amount; see figure).

PEPFAR’s creation marked a significant increase in the amount of funding provided by the U.S. for HIV. Trends in funding for bilateral programs and contributions to multilateral organizations are as follows (see the KFF fact sheet on the U.S. Global Health Budget: Global HIV Funding, Including PEPFAR and U.S. Global Health Budget: The Global Fund):

• Bilateral HIV Funding: The majority of PEPFAR funding (ranging from 70-77% each year over the past decade) is provided for bilateral programs through the State Department (most of which is then transferred to other agencies), USAID, CDC, and DoD. Bilateral funding rose rapidly from $822 million in FY 2003 (the year before PEPFAR) to a peak of $5.0 billion in FY 2010. Between FY 2010 and FY 2013, it declined by more than $750 million. While it has risen since then, bilateral funding in FY 2025 ($4.8 billion), which Congress provided through a continuing resolution, was still $233 million below its peak level, and funding has been mostly flat for the past several years.
• Multilateral Contributions: The U.S. also supports global HIV efforts through contributions to the Global Fund and UNAIDS. Support for the Global Fund, which accounts for most of the multilateral contributions, increased rapidly in its early years and fluctuated over time; it reached its highest level to date ($2.0 billion) in FY 2023. In FY 2025, funding for the Global Fund, which represented a carry-over from FY 2024 levels due to the continuing resolution, was $1.65 billion, $375 million less than the FY 2023 level, though this is due to a legislative requirement that limits the amount the U.S. can contribute to the Global Fund to not more than 33% of all contributions.²⁴  The U.S. contribution to UNAIDS was $45 million for most years over the past decade, but increased to $50 million in FY 2022, where it has remained.
• Emergency Funding: In FY 2021, an additional $3.8 billion in emergency supplemental funding was provided for bilateral HIV ($250 million) and the Global Fund ($3.5 billion) to address COVID-19.²⁵ 

Spending Directives²⁶ 

PEPFAR has included several spending directives, or earmarks, from Congress over the course of its history, many of which have changed over time:

1. The Leadership Act, PEPFAR’s original authorization, included the following spending directives: 55% of funds were to be spent on treatment; 15% on palliative care; 20% on prevention, of which at least 33% be spent on abstinence-until-marriage programs; and 10% on OVC. While these were included as “sense of Congress” recommendations, the treatment, OVC, and abstinence-until-marriage earmarks were made requirements as of FY 2006.
2. The Lantos-Hyde Act relaxed some of these directives for the FY 2009 – FY 2013 period: while still requiring that 10% of funds be spent on programs targeting OVC, it changed the treatment earmark from 55% to requiring that at least half of bilateral HIV assistance be spent on treatment and care. It removed the 33% abstinence-until-marriage directive and replaced it with a requirement of “balanced funding” for prevention to be accompanied by a report to Congress if less than half of prevention funds were spent on abstinence, delay of sexual debut, monogamy, fidelity, and partner reduction activities in any host country with a generalized (high prevalence) epidemic.
3. The PEPFAR Stewardship Act, The PEPFAR Extension Act, and recent short-term reauthorization have maintained the language in the Lantos-Hyde Act. With the expiration of the short-term reauthorization, eight timebound provisions have now lapsed.

PEPFAR & The Global Fund

The U.S. is the single largest donor to the Global Fund. Appropriations for the U.S. contribution to the Global Fund totaled approximately $31.5 billion from FY 2001 through FY 2025.²⁷  This includes, $3.5 billion in FY 2021 emergency funding that the U.S. government provided to the Global Fund to help the organization address the impacts of COVID-19 (in addition to the $250 million in emergency funds provided to bilateral HIV for COVID-19-related efforts).²⁸ 

The Global Fund provides another mechanism for U.S. support by funding programs developed by recipient countries, reaching a broader range of countries, and supporting TB, malaria, and health systems strengthening (HSS) programs in addition to (and beyond their linkage with) HIV.²⁹  To date, over 120 countries³⁰  have received Global Fund grants. Most Global Fund support (52%) has been committed to HIV and HIV/TB programs,³¹  followed by 29% to malaria, 15% to TB, and 4% to other health issues.³²  The original authorization of PEPFAR, and subsequent reauthorizations, included a limit on annual U.S. contributions to the Global Fund that prevented them from causing cumulative U.S. contributions to exceed 33% of the Global Fund’s total contributions (see the KFF fact sheet on the Global Fund). ^33 ,34 

1. KFF analysis of The Global Fund: https://data-service.theglobalfund.org/downloads. ↩︎
2. Totals represent funding specified by Congress in annual appropriations bills and/or identified by agencies for the Department of State, USAID, CDC, and DoD. In addition, international HIV research activities are supported by the NIH Office of AIDS Research (OAR) through its annual appropriated budget, but these amounts are not considered part of PEPFAR. See KFF’s “Breaking Down the U.S. Global Health Budget by Program Area” for additional information. ↩︎
3. UNAIDS. 2024 UNAIDS Global AIDS Update: The urgency of now – AIDS at the crossroads; July 2024. ↩︎
4. The U.S. first provided funding to address the global HIV epidemic in 1986. Then, in 1999, President Bill Clinton announced the Leadership and Investment in Fighting an Epidemic (LIFE) Initiative to address HIV in 14 African countries and in India. Later, in 2002, President George W. Bush announced the International Mother and Child HIV Prevention Initiative focused on 12 African and two Caribbean countries. ↩︎
5. PEPFAR. 2009 Annual Report to Congress; Jan. 2009. ↩︎
6. U.S. Congress. P.L. 108-25; May 27, 2003. ↩︎
7. KFF. The U.S. Government and Global Health, Sep. 2022. CRS. PEPFAR Reauthorization: Key Policy Debates and Changes to U.S. International HIV/AIDS, Tuberculosis, Malaria and Programs and Funding; Jan. 2009. ↩︎
8. U.S. Congress. Public Law No: 108-25; May 27, 2003. ↩︎
9. U.S. Department of State. “Leadership – Bureau of Global Health Security and Diplomacy” webpage, https://www.state.gov/leadership-bureau-of-global-health-security-and-diplomacy. ↩︎
10. Department of State. “ Leadership – Bureau of Global Health Security and Diplomacy,” webpage, https://www.state.gov/leadership-bureau-of-global-health-security-and-diplomacy/. ↩︎
11. PEPFAR. “About Us,” webpage, https://www.state.gov/about-us-pepfar/. ↩︎
12. Table 2 categorization is based on interventions laid out in the PEPFAR Financial Classification Reference Guide, used for program budgeting. See: PEPFAR Financial Classifications Reference Guide, June 2024. ↩︎
13. KFF. Funding for Key HIV Commodities in PEPFAR Countries; July 2021. ↩︎
14. PEPFAR. PEPFAR Latest Global Results; December 2024. ↩︎
15. The 15 African countries that are implementing DREAMS include Botswana, Cote d’Ivoire, Eswatini, Haiti, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Tanzania, Uganda, Zambia, and Zimbabwe. PEPFAR. DREAMS Country Fact Sheets; June 27, 2020; PEPFAR. PEPFAR Latest Global Results; December 2024. ↩︎
16. PEPFAR, “Where We Work” webpage, https://www.state.gov/where-we-work-pepfar/; PEPFAR 2023 Country Operational Plan Guidance for all PEPFAR Countries; and CDC’s “Where We Work” webpage, https://www.cdc.gov/global-hiv-tb/php/where-we-work/. ↩︎
17. The 25 countries that are required to complete a FY23 COP are Angola, Botswana, Burundi, Cameroon, Cote d’Ivoire, Democratic Republic of the Congo, Dominican Republic, Eswatini, Ethiopia, Haiti, Kenya, Lesotho, Malawi, Mozambique, Namibia, Nigeria, Rwanda, South Africa, South Sudan, Tanzania, Uganda, Ukraine, Vietnam, Zambia, and Zimbabwe.  PEPFAR. “Where We Work” webpage, https://www.state.gov/where-we-work-pepfar/. ↩︎
18. PEPFAR. 2023 Country and Regional Operational Plan Guidance and Technical Considerations; Feb. 2023. ↩︎
19. U.S. Congress. Public Law No: 112-25; Aug. 2, 2011. White House Office of Management and Budget (OMB). OMB Report to the Congress on the Joint Committee Sequestration for Fiscal Year 2013; March 1, 2013. KFF analysis of data from: Congressional appropriations bills and reports; Federal Agency Budget and Congressional Justification documents; ForeignAssistance.gov; KFF personal communication with the Office of Management and Budget. ↩︎
20. Overall PEPFAR funding technically includes support for bilateral HIV and TB activities, as well as contributions to multilateral organizations (specifically, the Global Fund and UNAIDS). This analysis only focuses on bilateral funding for HIV and contributions to multilateral organizations. ↩︎
21. UNAIDS is the Joint United Nations Programme on HIV/AIDS, the U.N. system’s coordinating body that serves to help galvanize worldwide attention to AIDS. ↩︎
22. Totals represent funding specified by Congress for PEPFAR in annual appropriations bills and/or identified by agencies for the Department of State, USAID, CDC, and DoD. In addition, international HIV research activities are supported by the NIH Office of AIDS Research (OAR) through its annual appropriated budget, but these amounts are not considered part of PEPFAR. See KFF’s “Breaking Down the U.S. Global Health Budget by Program Area” for additional information. ↩︎
23. Includes bilateral funding for HIV as well as U.S. contributions to UNAIDS and the Global Fund to Fight AIDS, Tuberculosis and Malaria through regular appropriations. ↩︎
24. U.S. Congress. Public Law No: 118-47; March 23, 2024. ↩︎
25. KFF analysis of data from the “American Rescue Plan Act of 2021” (P.L. 117-2). ↩︎
26. U.S. Congress. Public Law No: 108-25; May 27, 2003. U.S. Congress. Public Law No: 110-293; July 30, 2008. U.S. Congress. Public Law No: 113-56; Dec. 2, 2013. U.S. Congress. Public Law No: 115-305; Dec. 11, 2018. U.S. Congress. Public Law No: 118-47; March 23, 2024. ↩︎
27. Includes funding through regular appropriations and emergency supplemental funding. KFF analysis of data from: Congressional appropriations bills and reports; Federal Agency Budget and Congressional Justification documents; ForeignAssistance.gov; KFF personal communication with the Office of Management and Budget. ↩︎
28. KFF analysis of data from the “American Rescue Plan Act of 2021” (P.L. 117-2). ↩︎
29. Congress states that the Global Fund is the multilateral component of PEPFAR in the following: U.S. Congress. Public Law No: 110-293; July 30, 2008. U.S. Congress. Public Law No: 113-56; Dec. 2, 2013. ↩︎
30. Does not include countries that may have received funding through multi-country or regional programs. Additional countries may be reached through multi-country or regional programs. ↩︎
31. Of the 52% committed to HIV and HIV/TB programs, 39.4% was for HIV activities and 12.3% was for HIV/TB activities. ↩︎
32. In 2020, some donor governments provided COVID-specific emergency contributions to the Global Fund in addition to their contributions to core activities. For the purposes of this fact sheet, these COVID-specific amounts have been excluded as they cannot be attributed to a specific area, such as HIV, TB, or malaria. The Global Fund. Data Explorer; accessed July 2024: https://data.theglobalfund.org/. ↩︎
33. U.S. Congress. Public Law No: 108-25; May 27, 2003. U.S. Congress. Public Law No: 110-293; July 30, 2008. U.S. Congress. Public Law No: 113-56; Dec. 2, 2013. U.S. Congress. Public Law No: 118-47; March 23, 2024. KFF. PEPFAR Reauthorization: Side-by-Side of Legislation Over Time, brief. ↩︎
34. See the KFF. The U.S. & The Global Fund to Fight AIDS, TB and Malaria, fact sheet; and KFF. PEPFAR Reauthorization: Side-by-Side of Legislation Over Time, brief. ↩︎

The House and Senate are working on legislation to meet the requirements in the budget resolution, which targets cuts to Medicaid of up to $880 billion or more over 10 years. Although it is unclear what specific policies will be included in the final reconciliation bill, significant reductions in Medicaid spending would likely impact hospitals given that the program accounted for about one fifth (19%) of all spending on hospital care in 2023. Reductions in payments to hospitals, coupled with an increase in the number of uninsured Americans, resulting from Medicaid spending cuts or other policy changes would likely have implications for hospital finances, access to hospital services, the quality of patient care, and local economies (in that hospitals are the sixth largest employer in the country across industry subsectors).

The interactive map below shows the number of hospitals in each congressional district as reported in the American Hospital Association Annual Survey Database, updated through May 7, 2025. These counts include different types of hospitals, such as general, children’s, psychiatric, and long-term care hospitals. Federal hospitals, such as hospitals operated by the Department of Veterans Affairs, are excluded. (See Methods for additional information). Key takeaways include:

• There is at least one hospital in each of the 435 congressional districts, and as many as 69 hospitals in one district (KS01, which covers a large portion of the state).
• The large majority of congressional districts (94%) include at least five hospitals, most (61%) include at least ten hospitals, and about one in six (18%) include at least twenty hospitals.
• The average congressional district includes 14 hospitals.
• Republican congressional districts have 17 hospitals, on average, and Democratic districts have 10 hospitals, on average. Republican congressional districts may have more hospitals in part because they include some districts with large land areas, such as North Dakota, South Dakota, and Wyoming, each of which is one congressional district.

The Biden administration finalized several major Medicaid regulations with the intent of improving access to Medicaid services. Collectively, the rules span hundreds of pages of text, are extremely complex, and were set to be implemented over several years, with measurable increases in federal Medicaid spending. Overturning the rules would reduce regulation of managed care companies, nursing facilities, and other providers; increase barriers to enrolling in and renewing Medicaid coverage, and roll back enrollee protections, payment transparency, and requirements for improved access.

As Congress looks to meet the adopted budget resolution’s requirement of cutting federal Medicaid spending by up to $880 billion or more over ten years, overturning the Biden era rules could achieve some of those savings. Early leaked documents pointed to federal savings of $420 billion over ten years to roll back “major Biden Health rules,” although it is unclear which rules are included in the total and what the source is for the estimate. It is also unclear whether repealing all of the rules will be permissible under the Senate’s rules governing reconciliation legislation, which specify that provisions in reconciliation may not be “extraneous” to the federal budget.

To count as “savings” for the purposes of reconciliation, the federal budgetary effects of legislation changes must be estimated or “scored” by the Congressional Budget Office (CBO), raising the question of to what extent CBO will count repealing Biden era rules as savings for Medicaid. CBO has published its practices around how to incorporate administrative and judicial actions into cost estimates, explaining that after regulations are finalized, the effects of the rules are considered part of current law. The effects of repealing the regulations through legislation would, therefore, be included in a cost estimate, provided new regulations replacing the Biden rules aren’t proposed and assuming the courts don’t overturn any of the regulations (as new administrative or judicial action would change current law and may affect costs estimates). As of now, the only regulation for which savings are likely to be reduced because of administrative and judicial action is the requirement for nursing facilities to maintain minimum staffing levels (details below).

Major Medicaid health rules that could be repealed as part of reconciliation include the following:

• The Access rule addresses several dimensions of access: increasing provider rate transparency and accountability, standardizing data and monitoring, and increasing opportunities for Medicaid enrollees to provide feedback on state Medicaid policies through a new beneficiary advisory committee, with the goal of improving access to care.
• The rule requires states to compare fee-for-service (FFS) payment rates for primary care, obstetrical and gynecological care, and outpatient mental health and substance use disorder services to Medicare rates, and publish the analysis every two years, with the first analysis published by July 1, 2026.
• In addition, by July 1, 2026, states must publish all FFS rates on a publicly available and accessible website and make updates within one month of a payment rate change.
• The rule also included many provisions governing access to home care (also known as home- and community-based services or HCBS), which include ensuring that at least 80% of spending on certain services be spent on compensation for direct care workers and requiring states to report the number of people on waiting lists for care.
• The Managed Care rule addresses Medicaid managed care access, financing, and quality, including strengthening standards for timely access to care (e.g., through the establishment of national maximum wait time standards for certain “routine” appointments) and states’ monitoring and enforcement efforts. The rule requires states to submit annual payment analysis and establishes a ceiling on state directed payments to institutional providers like hospitals at “average commercial rates” or ACR. Other supplemental payments in fee-for-service use Medicare as the payment ceiling, which is generally substantially below what commercial insurers pay.
• The Long-Term Care Facility (LTC) Staffing rule establishes minimum staffing standards for nursing facilities, requires state Medicaid agencies to report the percent of Medicaid payments for institutional LTC that are spent on worker compensation, and provides funding for people to enter careers in nursing homes. It is unclear whether changes to the staffing rule would count as savings for reconciliation purposes because the US District Court for Northern Texas ruled to overturn the key staffing standards in early April. CBO generally does not account for district court rulings in its cost estimates but the Trump administration has signaled that it will not appeal the ruling, suggesting that in this case, the District Court decision may stand.
• Two rules streamline Medicaid enrollment and renewal processes for the Medicare Savings Program(MSP) and for Medicaid, CHIP and the Basic Health Program. The first rule helps eligible Medicare beneficiaries more easily access Medicaid coverage of Medicare premiums and cost sharing through the MSP while the second rule streamlines application and enrollment processes in Medicaid, aligns renewal policies for all Medicaid enrollees, including requiring states to renew eligibility only every 12 months for all Medicaid enrollees (a new requirement for people who qualify on the basis of age or disability pathways as 12-month renewals were already required for children and adults by the Affordable Care Act), facilitates transitions between Medicaid, CHIP, and subsidized Marketplace coverage, and eliminates certain barriers for children in CHIP. The rule also updates documentation and recordkeeping requirements to reduce payment errors based on insufficient documentation. Many provisions in the MSP rule have already taken effect and many states are already in compliance with other provisions ahead of scheduled implementation timelines. CBO estimates that repeal of these rules would reduce federal Medicaid spending by $170 billion over ten years and reduce Medicaid coverage by 2.3 million by 2034.